These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 15022309)

  • 1. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study.
    van Gaalen FA; Linn-Rasker SP; van Venrooij WJ; de Jong BA; Breedveld FC; Verweij CL; Toes RE; Huizinga TW
    Arthritis Rheum; 2004 Mar; 50(3):709-15. PubMed ID: 15022309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis.
    van Gaalen FA; van Aken J; Huizinga TW; Schreuder GM; Breedveld FC; Zanelli E; van Venrooij WJ; Verweij CL; Toes RE; de Vries RR
    Arthritis Rheum; 2004 Jul; 50(7):2113-21. PubMed ID: 15248208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort.
    Nicaise-Roland P; Nogueira L; Demattei C; de Chaisemartin L; Rincheval N; Cornillet M; Grootenboer-Mignot S; Dieudé P; Dougados M; Cantagrel A; Meyer O; Serre G; Chollet-Martin S
    Ann Rheum Dis; 2013 Mar; 72(3):357-62. PubMed ID: 22580581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.
    van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Huizinga TW; Toes RE; de Vries RR
    Arthritis Rheum; 2006 Apr; 54(4):1117-21. PubMed ID: 16572446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PREVALENCE OF ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN PATIENTS CLASSIFIED AS RHEUMATOID AND UNDIFFERENTIATED ARTHRITIS AT KENYATTA NATIONAL HOSPITAL.
    Ayunga AO; Oyoo GO; Amayo EO; Angela AA
    East Afr Med J; 2012 Jun; 89(6):206-11. PubMed ID: 26856043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis.
    van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Toes RE; Huizinga TW
    Arthritis Res Ther; 2005; 7(5):R949-58. PubMed ID: 16207336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
    Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
    Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response.
    Verpoort KN; Jol-van der Zijde CM; Papendrecht-van der Voort EA; Ioan-Facsinay A; Drijfhout JW; van Tol MJ; Breedveld FC; Huizinga TW; Toes RE
    Arthritis Rheum; 2006 Dec; 54(12):3799-808. PubMed ID: 17133560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis.
    Boire G; Cossette P; de Brum-Fernandes AJ; Liang P; Niyonsenga T; Zhou ZJ; Carrier N; Daniel C; Ménard HA
    Arthritis Res Ther; 2005; 7(3):R592-603. PubMed ID: 15899046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis.
    Verpoort KN; van Gaalen FA; van der Helm-van Mil AH; Schreuder GM; Breedveld FC; Huizinga TW; de Vries RR; Toes RE
    Arthritis Rheum; 2005 Oct; 52(10):3058-62. PubMed ID: 16200610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis.
    Kudo-Tanaka E; Ohshima S; Ishii M; Mima T; Matsushita M; Azuma N; Harada Y; Katada Y; Ikeue H; Umeshita-Sasai M; Miyatake K; Saeki Y
    Clin Rheumatol; 2007 Oct; 26(10):1627-33. PubMed ID: 17286215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-cyclic citrullinated peptide antibody predicts the development of rheumatoid arthritis in patients with undifferentiated arthritis.
    Li C; Zhang Y; Song H; Gao J; Zhao DB; Zhu Q; He DY; Wang L; Li XP; Liu XD; Xiao WG; Wu XY; Wu HX; Tu W; Hu SX; Wang X; Li ZJ; Lu ZM; Da ZY; Liang B; Liu XM; Zhao JW; Li L; Han F; Qi WF; Wei W; Ma X; Li ZB; Zheng GM; Zhang FX; Li Y; Wang YL; Ling GH; Chen JW; Hou XQ; Zhang J; Chen QP; Liu CL; Zhang Y; Zeng JS; Zou QH; Fang YF; Su Y; Li ZG
    Chin Med J (Engl); 2019 Dec; 132(24):2899-2904. PubMed ID: 31855969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study.
    Bizzaro N; Bartoloni E; Morozzi G; Manganelli S; Riccieri V; Sabatini P; Filippini M; Tampoia M; Afeltra A; Sebastiani G; Alpini C; Bini V; Bistoni O; Alunno A; Gerli R;
    Arthritis Res Ther; 2013 Jan; 15(1):R16. PubMed ID: 23339296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis.
    van Venrooij WJ; Zendman AJ; Pruijn GJ
    Autoimmun Rev; 2006 Nov; 6(1):37-41. PubMed ID: 17110315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining anti-cyclic citrullinated peptide with the American College of Rheumatology 1987 criteria failed to improve early rheumatoid arthritis diagnosis in the community-based very early arthritis cohort.
    Le Loët X; Strotz V; Lequerré T; Boumier P; Pouplin S; Mejjad O; Daragon A; Jouen F; Vittecoq O; Fardellone P; Ménard JF
    Rheumatology (Oxford); 2011 Oct; 50(10):1901-7. PubMed ID: 21750000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of third generation anti-CCP antibodies in the diagnosis of rheumatoid arthritis from undifferentiated polyarthritis after 4 years of follow-up.
    Caro-Oleas JL; Fernández-Suárez A; Reneses Cesteros S; Porrino C; Núñez-Roldán A; Wichmann Schlipf I
    Clin Exp Rheumatol; 2008; 26(3):461-3. PubMed ID: 18578970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated anticitrullinated protein antibody and rheumatoid factor assessment is not necessary in early arthritis: results from the ESPOIR cohort.
    Gossec L; Paternotte S; Combe B; Meyer O; Dougados M
    J Rheumatol; 2014 Jan; 41(1):41-6. PubMed ID: 24241481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.
    Schellekens GA; Visser H; de Jong BA; van den Hoogen FH; Hazes JM; Breedveld FC; van Venrooij WJ
    Arthritis Rheum; 2000 Jan; 43(1):155-63. PubMed ID: 10643712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis.
    van der Woude D; Rantapää-Dahlqvist S; Ioan-Facsinay A; Onnekink C; Schwarte CM; Verpoort KN; Drijfhout JW; Huizinga TW; Toes RE; Pruijn GJ
    Ann Rheum Dis; 2010 Aug; 69(8):1554-61. PubMed ID: 20448290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.